CoChat

Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy

Open access
Sofjan, Amelia K., Mitchell, Ardath, Shah, Dhara N., Nguyen, Tam, Sim, Mui, Trojcak, Ashley, Beyda, Nicholas D., Garey, Kevin W. · 2018 · Journal of Global Antimicrobial Resistance
Cited by 95

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: Rezafungin (CD101) is a novel echinocandin currently under development. The purpose of this study was to perform a systematic literature review of published evidence on rezafungin and an antimicrobial stewardship audit of real-world use of echinocandins to determine areas of unmet medical needs and potential places in therapy for rezafungin. METHODS: The systematic literature review identified 8 peer-reviewed manuscripts and 19 separate abstracts. A stewardship audit was performed on hospitalised patients receiving echinocandins to better understand potential future areas of use for rezafungin. RESULTS: Rezafungin is a cyclic hexapeptide with a lipophilic tail derived from anidulafungin, with a choline moiety at the C5 ornithine position resulting in increased in vitro and in vivo stability compared with other echinocandins. Microbiological data showed similar susceptibility and resistance development between rezafungin and other echinocandins. Rezafungin has a long half-life (80h) and a favourable safety profile that allows for high doses (up to 400mg) given once weekly. A phase 2 study is ongoing. The antimicrobial stewardship audit of echinocandin identified several areas of possible use for rezafungin, including patients receiving daily echinocandins for >7 days, patients who remained in the hospital to complete a full course of daily echinocandin therapy, and patients who required an echinocandin scheduled via an infusion clinic after discharge. CONCLUSION: Rezafungin is a novel echinocandin currently in phase 2 studies, differentiated by a long half-life that allows once-weekly dosing and a safety profile that allows higher doses. Several potential areas of use for rezafungin were identified.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jgar.2018.02.013

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 95

Metadata

Authors
Sofjan, A. K., Mitchell, A., Shah, D. N., Nguyen, T., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W.
Venue
Journal of Global Antimicrobial Resistance
Publisher
Elsevier BV
Published
2018-09
Volume
14
Pages
58-64
ISSN
2213-7165 (ISSN-L)
OpenAlex
W2792867432
Cited by
95
References
9
FWCI
1.79
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. https://app.cochat.ai/papers/10.1016/j.jgar.2018.02.013
The paper
Sofjan, A. K., Mitchell, A., Shah, D. N., Nguyen, T., Sim, M., Trojcak, A., Beyda, N. D., & Garey, K. W. (2018). Rezafungin (CD101), a next-generation echinocandin: A systematic literature review and assessment of possible place in therapy. Journal of Global Antimicrobial Resistance. https://doi.org/10.1016/j.jgar.2018.02.013

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.